Conception et réalisation d'une unité de synthèse automatisée pour la préparation du [18F]-FMPEP-d2.

[18F]-FMPEP-d2 制备的自动化合成单元的概念和实现。

• 批准号: 538082-2019
• 负责人: Guérin, Brigitte
• 金额: $ 1.82万
• 依托单位: Université de Sherbrooke
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=680385
• 关键词: Conception; et; alisation; une; unit

Inversago Pharma is a biotechnology company specializing in the development of new types of inverse agonists and antagonists of the cannabinoid type 1 (CB1) receptor for the treatment of several metabolic disorders such as diabetes (type II) in a more targeted way and therefore, causing fewer side effects. The company wants to perform efficacy and safety tests on this type of molecule by positron emission tomography (PET) imaging in order to market them, but to do this, Inversago Pharma must first find a way to synthesize a radiotracer for a better validation. For radioprotection reasons, complete automation of radiotracer synthesis is mandatory. A dedicated synthesis unit is also essential to avoid contamination and to reproduce optimal reaction and purification conditions. The research team of Pre Guérin therefore proposes, within the framework of this project, to design and build a synthesis unit or box in which all the stages of the radiotracer synthesis can be performed in an automated way while respecting both the radiation protection standards and the needs of the partner.

Inversago Pharma是一家生物技术公司，专门研究大麻素1型（CB1）受体的新型反向激动剂和拮抗剂，以更具针对性的方式治疗多种代谢性疾病，例如糖尿病（II型），因此会导致较少的副作用。该公司希望通过极地发射断层扫描（PET）成像对这种类型的分子进行有效性和安全测试，以销售它们，但是为此，Inversago Pharma必须首先找到一种方法来合成放射性示例以进行更好的验证。出于放射保护原因，必须完全自动化放射性示意剂合成。专用的合成单元对于避免污染和再现最佳反应和纯化条件也至关重要。因此，Guérin前的研究团队在该项目的框架内提议设计和建立一个合成单元或盒子，其中可以自动执行radiotracer合成的所有阶段，同时尊重辐射保护标准和合作伙伴的需求。